Project Grant R01CA303612
Award Date 7/10/26
Completion Date 6/30/31
Dollars Obligated $551K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Palo Alto, CA 94304, USA
Similar Awards
- Grant Award Summary The Beckman Research Institute of the City of Hope received a $733,864 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective June 1, 2026, through May 31, 2031. The research project aims to identify and characterize stimulatory immune checkpoints that regulate macrophage-mediated programmed cell removal (PRCR) in tumor surveillance. Using high-throughput CRISPR-based screening and preclinical...
- Federal Grant Award Summary The Beckman Research Institute of the City of Hope received a $694,015 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), awarded July 1, 2026, with a completion date of June 30, 2031. The research project, titled "Identifying and Targeting Cancer Immune Evasion Signals Against Macrophage Surveillance," focuses on identifying and characterizing phagocytosis checkpoints that regulate macrophage-mediated...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $677,787 to The Regents of the University of California, San Francisco on August 26, 2025, under the Cancer Treatment Research program (CFDA 93.395). The award supports a five-year research initiative (through July 31, 2030) investigating AIRE-expressing tumor-associated macrophages (AIRE+ TAMs) as novel mediators of tumor immune evasion. The research aims to characterize the molecular and...
- Federal Project Grant Award Summary Funding Agency: National Cancer Institute (NCI) Federal Grant Program: Cancer Biology Research (CFDA 93.396) Award Amount: $697,131 Award Date: May 1, 2026 Project Completion Date: April 30, 2031 Awardee: Icahn School of Medicine at Mount Sinai, New York, NY This five-year Project Grant supports fundamental cancer biology research investigating the myeloid-stromal axis in colorectal cancer (CRC) immunosuppression and resistance to immune checkpoint blockade...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research a Project Grant of $671,252 under the Cancer Biology Research program (CFDA 93.396), effective July 1, 2026, through June 30, 2031. This five-year research initiative investigates the mechanisms by which CD4 T cells and dendritic cells (DC) work in concert with CD8 T cells to enhance anti-tumor immunity. Specifically, the research focuses on understanding how...
- The National Cancer Institute (NCI) awarded $126,220 to The Trustees of The University of Pennsylvania under the Cancer Research Manpower program (CFDA 93.398) on September 10, 2025, with a completion date of May 31, 2026. This Project Grant supports biomedical research training focused on elucidating the mechanisms of lymphatic metastasis in pancreatic ductal adenocarcinoma (PDAC). The research investigates how regulatory T cells (Tregs) intrinsically suppress anti-tumor immune responses within...
- The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $302,228 project grant to The Regents of the University of California, San Francisco to support research on "Establishing and Overcoming the Mechanisms of Liver Metastasis-Induced Systemic Tumor Immune Tolerance and Immunotherapy Resistance in Melanoma." The 3-year grant project, running from September 30, 2023 to September 29, 2026, will investigate the biological mechanisms by...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Leland Stanford Junior University a $357,370 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on May 5, 2026, to support research on reprogramming inflammatory fibroblasts to overcome therapeutic resistance in pancreatic ductal adenocarcinoma (PDAC). The project, which will extend through April 30, 2031, focuses on understanding cancer-associated fibroblasts (CAFs)—specifically a unique...
- Federal Project Grant Award Summary The National Cancer Institute (National Institutes of Health) awarded The Trustees of The University of Pennsylvania a Project Grant of $594,899 under the Cancer Treatment Research program (CFDA 93.395) to conduct basic and translational research on glioblastoma (GBM) immunotherapy. The five-year research initiative, initiated July 6, 2026 and concluding June 30, 2031, focuses on understanding the vascular regulation of macrophage function in brain tumors...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a Project Grant totaling $658,423 under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2026 through June 30, 2031. This award supports fundamental research on therapeutic targeting of PI3K gamma (PI3Kγ)-positive tumor-associated macrophages (TAMs) in metastatic castration-resistant prostate cancer (MCRPC) to reduce health disparities. The research builds on the investigator...